Estimating Preclinical Alzheimer's Disease Populations by <i>p</i> ‐tau217 in the United States, Japan, Germany, and China

Given the estimated scale of the preclinical AD population, BBMs like plasma p-tau217 may help reduce the burden on healthcare system infrastructure and budgets by identifying those at greatest risk of progression, who may be benefit from future treatments. Data on prevalence of plasma p-tau positivity in the preclinical AD population is needed for robust estimates that will help determine economic impact of future treatment.